International Clinical Trial: A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465289) titled 'A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis' on March 6.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: UCB Biopharma SRL

Condition: Ocular Myasthenia Gravis

Intervention: Drug: Rozanolixizumab

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: July 27, 2026

Target Sample Size: 100

To know more, visit https://clinicaltrials.gov/study/NCT07465289

Published by HT Digital ...